From Bench to Bedside: The Evolution of Tissue-engineered Maxillofacial Reconstruction – Conceptualizing the practicality of in-situ tissue engineering for our patients in the modern era

First conceptualized by W.T. Green in the 1970s, the advent of tissue engineering was a significant milestone in the field of medicine and surgery. What started as proof-of-concept studies in preclinical models has transitioned to clinically applicable regenerative strategies for maxillofacial reconstruction in patients. Tissue-engineered bone grafts have made the reconstruction of defects of the oral and maxillofacial region predictable and reliable without the need for harvesting autogenous bone. The focus of this session will be on the two fields where the most significant advancements have occurred, craniofacial bone and sensory nerves. Multiple long-term clinical studies have demonstrated tissue-engineered bone grafts and allogeneic nerve reconstruction are equivalent or even superior to autogenous grafts. The "bench" part of this session will introduce and discuss the science regarding bone and nerve repair and regeneration. The "bedside" session will focus on key concepts for the successful clinical application of tissue engineering science to bone and nerve repair. This session will briefly discuss preoperative workup, preparation, and procedural options for patients with tumors, post-resection defects, and traumatic defects. Focus areas will include surgical technique, postoperative care and the management of complications.

Learning Objectives

At the conclusion of this program, participants should be able to:

  1. Discuss the science behind bone grafts, tissue-engineering graft, allogeneic nerve regeneration. 
  2. Review surgical techniques to optimize bone and nerve regeneration and patient outcomes. 
  3. Discuss surgical technique and management of complications. 

James C. Melville, DDS FACS
Associate Professor of Oral and Maxillofacial Surgery
Bernard & Gloria Pepper Katz Department of Oral & Maxillofacial Surgery, Oral & Head and Neck Oncology and Microvascular Reconstructive Surgery University of Texas Health Science Center at Houston
Houston, Texas
Disclosure: AxoGen Inc (Individual(s) Involved: Self): Consultant/Advisory Board; Integra LifeSciences (Individual(s) Involved: Self): Consultant/Advisory Board; Johnson & Johnson (Individual(s) Involved: Self): Consultant/Advisory Board; Proteocyte Diagnostics (Individual(s) Involved: Self): Consultant/Advisory Board

Simon W. Young, DDS, MD, Ph.D
Associate Professor
Bernard & Gloria Pepper Katz Department of Oral & Maxillofacial Surgery, Director of Research
Houston, Texas
Disclosure: KLS Martin (Individual(s) Involved: Self): Research Grant; Privo Technologies (Individual(s) Involved: Self): Research Grant; Proteocyte Diagnostics (Individual(s) Involved: Self): Consultant/Advisory Board; Stryker Craniomaxillofacial Inc. (Individual(s) Involved: Self): Research Grant

An Internet-based CDE/CME Activity
Original Release Date: September 12, 2022
Expiration Date: September 12, 2025
Estimated time to complete this educational activity: 1.0 hours
Method of participation: Self-Study

James C. Melville, DDS, FACS

Associate Professor

University of Texas Health Science Center at Houston

James C. Melville, DDS, FACS, is an Associate Professor in the Department of Oral and Maxillofacial Surgery at the University of Texas Health Science Center at Houston UTHealth and specializes in Oral, Head & Neck Oncology, and Microvascular Reconstructive Surgery. He graduated from the University of Michigan School of Dentistry in Ann Arbor, Michigan, in 2005 and completed a General Practice Residency at the University of California San Francisco in 2006. He completed a residency in oral and maxillofacial surgery in 2012, followed by fellowships in oral, head, and neck oncology and microvascular reconstructive surgery at the University of Miami/Jackson Memorial Hospital. He was appointed to the UTH OMFS internship director in 2017.

Dr. Melville was awarded the Faculty Educator Development Award (FEDA) in 2019 by the American Association of Oral & Maxillofacial Surgeons (AAOMS). An award given to promising young academic surgeons. He was awarded the AAOMS Advocacy Challenge Coin by the AAOMS Board of Trustees and AAOMS Committee on Government Affairs in 2020. AAOMS designed its own Challenge Coin to recognize oral and maxillofacial surgeons who have made significant advocacy contributions on behalf of the Association. The AAOMS Challenge Coin is awarded to those elite few who transcend the efforts of their colleagues to further the specialty through advocacy. Dr. Melville serves as the Vice-President of the Oral & Maxillofacial Section of the American Association for Dental, Oral, and Craniofacial Research (AADOCR) / International Association of Dental Researchers (IADR) and will be become the President in 2023. He was appointed the Vice President of the AAOMS Clinical Interest Group (CIG) in Neurologic Disorders 2021. He also serves on the International Academy of Oral Oncology (IAOO) as a scientific committee member for its 2022 conference.

Dr. Melville is a diplomate and examiner of the American Board of Oral and Maxillofacial Surgery and a fellow of the American Association of Oral and Maxillofacial Surgeons, the American Academy of Craniomaxillofacial Surgeons, American College of Oral & Maxillofacial Surgeons, and the American College of Surgeons. He has been an invited visiting professor and lecturer at over 15 academic institutions including Case Western University, Columbia University, Harvard/MGH, Emory University, Johns Hopkins University, University of Michigan, UOP/ Stanford University UCLA, USC, and UCLA.

He has written a Springer textbook on maxillofacial reconstruction and contributed to 25 chapters in textbooks concerning oral and maxillofacial surgery, oncology, maxillofacial reconstruction, microvascular reconstruction, and tissue engineering. In addition, he is the author of more than 40 articles in peer-reviewed journals. He is a reviewer for the Journal of Oral and Maxillofacial Surgery (JOMS), Triple OOOO Journal, Journal of Cranio-Maxillofacial Surgery, Journal of Tissue Engineering, PLOS ONE, Bioengineering & Translational Medicine (Wiley), Journal of Biomedical Materials Research, Experimental Dermatology, Japanese Dental Science Review, and of Journal of American Dental Association (JADA).

Disclosure(s): AxoGen, Inc.: Consultant (Ongoing); Proteocyte AI, Toronto: Consultant (Ongoing)

Simon Young, DDS, MD, PhD, FACS

Associate Professor, Director of Research

University of Texas Health Science Center at Houston

Simon Young, DDS, MD, PhD, FACS, is Associate Professor and Director of Research in the Department of Oral and Maxillofacial Surgery, The University of Texas Health Science Center at Houston, School of Dentistry. He completed his DDS at the Faculty of Dentistry, University of Toronto, in 2003, his PhD at Rice University, Department of Bioengineering, Houston, Texas, in 2008, and his MD at University of Texas Medical School at Houston in 2011. He subsequently completed first an Oral & Maxillofacial Surgery Residency at University of Texas Health Science Center at Houston and then a Postdoctoral Research Fellowship in Immuno-Engineering at Harvard University, School of Engineering and Applied Sciences. Dr. Young is a Diplomate of the American Board of Oral and Maxillofacial Surgery. He is the author of over 40 articles in peer-reviewed journals and has an NIH-funded laboratory that studies biomaterials-based cancer immunotherapies and maxillofacial tissue engineering.

Disclosure(s): Amend Surgical: Consultant (Ongoing); KLS Martin: Research Grant or Support (Ongoing); Proteocyte AI, Toronto: Consultant (Ongoing)

Continuing Education Provider Approval
The American Association of Oral and Maxillofacial Surgeons is an ADA CERP Recognized Provider.

ADA CERP is a service of the American Dental Association to assist dental professionals in identifying quality providers of continuing dental education.

ADA CERP does not approve or endorse individual courses or instructors, nor does it imply acceptance of credit hours by boards of dentistry.

The American Association of Oral and Maxillofacial Surgeons designates this activity for 1.0 continuing education credit(s).

AGD - Accepted Program Provider
FAGD/MAGD Credit
11/1/22-12/31/26
Provider ID# 214680

The American Association of Oral and Maxillofacial Surgeons (AAOMS) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Association of Oral and Maxillofacial Surgeons designates this internet-based enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Key:

Complete
Failed
Available
Locked
Faculty and Planner Disclosure
Pre-Quiz
4 Questions  |  1 attempt  |  0/4 points to pass
4 Questions  |  1 attempt  |  0/4 points to pass
From Bench to Bedside: The Evolution of Tissue-engineered Maxillofacial Reconstruction – Conceptualizing the practicality of in-situ tissue engineering for our patients in the modern era
Open to view video.
Open to view video.
Post-Quiz
4 Questions  |  Unlimited attempts  |  3/4 points to pass
4 Questions  |  Unlimited attempts  |  3/4 points to pass
Evaluation
11 Questions
Certificate
1.00 CDE/CME credit  |  Certificate available
1.00 CDE/CME credit  |  Certificate available